The Ethics of Innovation: Disability, Technology, and Reproductive Justice – with Katie Hasson
By Keith Casebonne and Jodi Beckstine [with CGS' Katie Hasson],
Disability Deep Dive
| 07. 24. 2025
In this episode of Disability Deep Dive, hosts Keith and Jodi explore the complex interplay between disability science, technology, and ethics with guest Katie Hasson, Associate Director at the Center for Genetics and Society. The conversation delves into the ethical concerns surrounding genetic technologies, the medical vs. social model of disability, and the risk of eugenics in current bioethical practices. Katie also highlights the Center's work in ensuring social justice and equity in biotechnologies, and emphasizing the importance of including disabled voices in policy discussions. The episode concludes with a discussion on the documentary 'Fixed: The Science/Fiction of Human Enhancement,' which examines the impact of biotechnology on the disabled community.
Episode Transcript
Jodi Beckstine (00:01):
Want to talk and explore how disability science and ethics collide in today's tech-driven world? We're diving headfirst into the ethics of innovation on this episode of Disability Deep Dive.
Keith Casebonne (00:38):
Hello, listeners. We are really glad you're here. I'm Keith.
Jodi Beckstine (00:41):
And I'm Jody. Welcome back to Disability Deep Dive.
Keith Casebonne (00:45):
Today's episode is called the...
Related Articles
By Jenny Lange, BioNews | 12.01.2025
A UK toddler with a rare genetic condition was the first person to receive a new gene therapy that appears to halt disease progression.
Oliver, now three years old, has Hunter syndrome, an inherited genetic disorder that leads to physical...
By Grace Won, KQED [with CGS' Katie Hasson] | 12.02.2025
In the U.S., it’s illegal to edit genes in human embryos with the intention of creating a genetically engineered baby. But according to the Wall Street Journal, Bay Area startups are focused on just that. It wouldn’t be the first...
By Pam Belluck and Carl Zimmer, The New York Times | 11.19.2025
Gene-editing therapies offer great hope for treating rare diseases, but they face big hurdles: the tremendous time and resources involved in devising a treatment that might only apply to a small number of patients.
A study published on Wednesday...
Several recent Biopolitical Times posts (1, 2, 3, 4) have called attention to the alarmingly rapid commercialization of “designer baby” technologies: polygenic embryo screening (especially its use to purportedly screen for traits like intelligence), in vitro gametogenesis (lab-made eggs and sperm), and heritable genome editing (also termed embryo editing or reproductive gene editing). Those three, together with artificial wombs, have been dubbed the “Gattaca stack” by Brian Armstrong, CEO of the cryptocurrency company...
